Basel, Switzerland, 06 October 2025 – Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), today announced the launch of TheraPEAK®
AmpliCell®
Cytokines and TheraPEAK®
293-GT®
Medium to expand its GMP solutions for cell and gene therapy.
Cytokines represent a critical component in cell therapy manufacturing, supporting the expansion and maintenance of living cells. TheraPEAK®
AmpliCell®
Cytokines enable the reliable expansion, activation, and differentiation of immune cells. Produced in a mammalian expression system and engineered for high biological activity, these cytokines feature proper folding and glycosylation, delivering native-like structure and function that bacterial systems cannot match. This ensures superior biological relevance, batch-to-batch consistency, and greater predictability in sensitive and translational applications, both in research and GMP set-ups.
TheraPEAK®
293-GT®
Medium is a chemically defined, animal–origin–free system optimized for adeno-associated virus (AAV) production in suspension HEK293 cells, providing a reliable, scalable option for advancing gene therapy programs. Unlike off-the-shelf viral production kits that may lack flexibility, the 293-GT®
System (growth medium plus supplement) is a drop-in-ready solution engineered to integrate seamlessly with existing workflows. The media is compatible with commercially available transfection reagents and AAV enhancers, delivers strong AAV titers, and supports high full-to-empty capsid ratios.
TheraPEAK®
Products have been used in FDA-approved therapies and more than 130 clinical trials across the globe. The newly-added solutions provide researchers and manufacturers with high-performance, scalable, and regulatory-ready solutions that streamline cell and gene therapy workflows from discovery through clinical development.
Mike Goetter, Head of Bioscience, Specialized Modalities, Lonza, said: “The introduction of AmpliCell®
Cytokines and the 293-GT®
Medium to our TheraPEAK®
Range greatly enhances our offering for cell and gene therapy customers, providing them with reliable solutions to support their drug development efforts.”
Additional Information
To learn more about Lonza’s TheraPEAK®
products, visit:
https://bioscience.lonza.com/consistency-you-can-count-on-therapeak-amplicell-cytokines
Lonza Contact Details
media@lonza.com
Disclaimer
Certain matters discussed in this media advisory may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to
update the statements contained in this media advisory.
Privacy Policy